Please ensure Javascript is enabled for purposes of website accessibility

Merck CEO Kenneth Frazier Stepping Down

By Eric Volkman - Feb 4, 2021 at 5:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Current CFO Robert Davis will be his replacement.

One prominent pharmaceutical company is about to swap out its CEO. Merck (MRK 0.50%) announced Thursday that its current leader, Kenneth Frazier, is retiring from his post, effective June 30. It did not provide any reason for his departure. He will be replaced by the company's present CFO, Robert Davis, who will also be given a seat on the board of directors.

Meanwhile, Frazier will continue to hold the position of executive chairman of the board for a "transition period." The length of this period will be decided by the board.

The company doesn't exactly change its leadership often; Frazier has occupied the CEO throne since 2011. He joined the company in 1992 as a general counsel.

Merck HQ in New Jersey.

Merck headquarters in New Jersey. Image source: Getty Images.

Davis has been with Merck since 2014, when he was appointed CFO. In Merck's press release announcing the moves, Davis said that he intends to keep his predecessor's emphasis on innovation. The end goal is "to be the premier research-intensive biopharmaceutical company," he said.

The announcement of Frazier's retirement and Davis' promotion came on the same day as the release of Merck's fourth-quarter 2020 results. On both the top and bottom lines, the company's performance didn't meet analyst expectations, with the coronavirus pandemic hurting much of its business.

On a more positive note, its star blockbuster drug, immuno-oncology treatment Keytruda, is still making a meaningful contribution, with double-digit sales growth during the quarter.

On Thursday, Merck stock was down by 1.7%, against the 1.1% rise in the S&P 500 index.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$91.04 (0.50%) $0.45

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
402%
 
S&P 500 Returns
129%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.